Interactive scientific summary

Introduction Martin Reck Grosshansdorf, Germany The symposium Chair Professor Martin Reck, from Lung Clinic Grosshansdorf in Germany, opened the independent satellite symposium with an overview of squamous non-small-cell lung cancer (NSCLC). Eight-five percent of all lung cancer cases are non- small-cell in nature, he said, and of these, 20–30% have squamous histology 1 (Figure 1). Squamous NSCLC is a “distinct disease”, said Reck, both morphologically and also in terms of clinical presentation, with centrally located tumours that are found more commonly in men, smokers and older patients 2–6 . The prognosis of patients with squamous histology is poor, and research into treatment options for these patients has proved “extremely challenging”. The Chair observed that trials of new agents and combinations have mostly been negative with no overall survival (OS) improvements for patients, while certain drugs have induced a “severe safety risk” in patients with advanced squamous disease 7–15 . Click here to view a clip from Professor Reck’s presentation Figure 1: Epidemiology of NSCLC 1 Springer Healthcare IME | 6 Navigating the advanced NSCLC patient pathway: newmarkers and targets European Lung Cancer Conference – Geneva, 2016